Johan de Rooij received his masters degree (cum laude) from Wageningen University in 1996 (molecular sciences). He received his PhD from Utrecht University in 2000, in the lab of Hans Bos where he identified a family of Guanine-nucleotide Exchange Factors, among which the cAMP-target Epac. Based on this work, he was employed from 2000-2002 by a start-up pharmaceutical company Semaia, with the objective to identify small-molecule modifiers of Rap signaling. In the meantime Johan was awarded a fellowship from the Dutch Cancer Society (KWF) to study the balance between cell-cell and cell-matrix adhesion during malignant transformation at the Scripps Research Institute in La Jolla (USA) under the supervision of Clare Waterman and Martin Schwartz (2002-2005). In 2005 he returned to the Netherlands to continue this line of research at the Netherlands Cancer Institute. He received grants from the Association for International Cancer Research (AICR), KWF and Netherlands Organization for Scientific Research (NWO) and moved in 2008 to the Hubrecht Institute to become a junior group leader and expand his work on the regulation and dynamics of cell adhesion.
About the research